| Autor: |
Sargeele Silva, Rafael Grochot, Debora Cristina Weschenfelder, Cláudio Pescador, Catherine Gotardo, Diego Gnatta, André Reiriz, Janaina Brollo |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Brazilian Journal of Oncology, Vol 15, Iss (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2526-8732 |
| DOI: |
10.5935/2526-8732.20190012 |
| Popis: |
The paclitaxel-cisplatin is a non-infusional alternative for induction chemotherapy (IC) for LASCCHN based on phase-II trials. Here, we describe our institutional experience with this combination in Southern Brazil. Methods: Thirty-three consecutive patients with unresectable LASCCHN were selected between April/2012 and June/2014. They received weekly paclitaxel 80mg/m2 on days 1, 8, 15 and cisplatin 75mg/m2 on day 1 for three cycles followed by chemoradiotherapy (CRT) with cisplatin at standard dose. Overall response, toxicity, progression free survival (PFS) and overall survival (OS) were evaluated. Results: The median follow-up was 25.5 months. Median age was 58.6 years and 96% had PS 1. Most patients presented with bulky disease at stages IVA and IVB (60.6% and 21.2%, respectively). Concerning primary site of tumor, 33.3% were oropharingeal tumors, 27.3% larynx tumors and 33.3% oral cavity tumors. The majority of patients had both smoking and alcohol abuse records. Twenty-eight patients (84.8%) at the time of diagnosis had a BMI |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
